Se Jin Im
Se Jin Im PhD
Professor: Graduate Program, Research Area, Laboratory, E-mail, Tel
Graduate Program Infection and Immunity
Research Area Cellular Immunology
Laboratory Infection and Tumor Immunology Laboratory (I&TI lab) Laboratory
Tel +82-31-299-6125
Education & Careers
  • 2000-2012 POSTECH, B.S. / Ph.D
    2012-2019 Emory Univ., Postdoc Fellow / Asc. Scientist / Research Asc.
    2020-present Sungkyunkwan Univ., Assistant Prof.
Research Interest
The long-term goal of Dr. Im’s research is to understand the mechanisms of T cell immunity in disease models having highly sustained antigen levels such as chronic viral infection, cancer, and autoimmune disease and to use this information to develop new immunotherapeutics for the treatment of the diseases.

A. T cell exhaustion during chronic viral infections and cancer
B. Immunotherapy for cancer
i) Therapeutic antibodies against new immunomodulatory proteins
ii) Adoptive T cell therapy using endogenous tumor-specific CD8 T cells
C. Biomarkers for immune-checkpoint blockades in cancer patients
Representative Research Achievements
  • 1. Im SJ, Konieczny BT, Hudson WH, Masopust D and Ahmed R. PD-1+ stemlike CD8 T cells are resident in lymphoid tissues during persistent LCMV infection. Proc Natl Acad Sci USA (2020) 117(8):4292 (IF: 9.504)

    2. Jansen CS, Prokhnevska N, Master V, Sanda M, Carlisle JW, Bilen MA, Cardenas M, Wilkinson S, Lake R, Sowalsky AG, Valanparambil RM, Hudson WH, McGuire D, Melnick K, Khan AI, Kim K, Chang YM, Kim A, Filson C, Alemozaffar M, Osunkoya AO, Mullane P, Ellis C, Akondy R, Im SJ, Kamphorst A, Reyes A, Liu Y and Kissick HT. An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature (2019) 576(7787):465 (IF: 41.577)

    3. Hudson WH, Gensheimer JL, Hashimoto M, Wieland A, Valanparambil RM, Li P, Lin JX, Konieczny BT, Im SJ, Freeman GJ, Leonard WJ, Kissick HT and Ahmed R. Proliferating transitory T cells with an effector-like transcriptional signature emerge from PD-1+ stem-like CD8+ T cells during chronic infection. Immunity (2019) 51(6):1043 (IF: 19.744)

    4. *Jadhav RR, *Im SJ, *Hu B, Hashimoto M, Li P, Leonard WJ, Greenleaf WJ, &9768Ahmed R and &9768Goronzy JJ. Epigenetic signature of PD-1+TCF1+ CD8 T cells that act as resource cells during chronic viral infection and respond to PD-1 blockade. (*Co-first authors, &9768Co-corresponding authors) Proc Natl Acad Sci USA (2019), 116 (28):14113 (IF: 9.504)

    5. Im SJ, Hashimoto M, Gerner MY, Lee J, Kissick HT, Burger MC, Shan Q, Hale JS, Lee J, Nasti TH, Sharpe AH, Freeman GJ, Germain RN, Nakaya HI, Xue HH and Ahmed R. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature (2016) 537(7620):417 (IF: 40.137)
    - This article is highlighted in News and Views of same issue of Nature (2016) 537(7620):312.